Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

References

• Global Burden of Disease Cancer C. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.2996.
   Web of Science ®Google Scholar
• Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012;380:1797–11. doi:10.1016/S0140-6736(12)61688-2.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del Gaizo F, Colantuoni G, Nicolella D, Napolitano L. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol. 2006;17(Suppl 5):v72–78. doi:10.1093/annonc/mdj955.
   PubMed Web of Science ®Google Scholar
• Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol. 2015;38:422–430. doi:10.1097/COC.0000000000000059.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232. doi:10.1016/1040-8428(94)00144-I.
   PubMed Web of Science ®Google Scholar
• Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res. 2000;6:4607–4609.
   PubMed Web of Science ®Google Scholar
• Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992;4:1–24. doi:10.1016/0955-2235(92)90002-Y.
   PubMedGoogle Scholar
• Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8:11–31. doi:10.1677/erc.0.0080011.
   PubMed Web of Science ®Google Scholar
• Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, et al. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer. 2016;16:354. doi:10.1186/s12885-016-2392-0.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Takamura H, Ninomiya I, Fushida S, Tsugawa K, Kaji M, Nakai Y, Ohoyama S, Yamaguchi A, Miyazaki I. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology. 1992;49:157–161. doi:10.1159/000227031.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27:3944–3956. doi:10.1038/onc.2008.19.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005;65:9176–9184. doi:10.1158/0008-5472.CAN-05-1556.
   PubMed Web of Science ®Google Scholar
• Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998;4:241–249.
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol. 2003;14:461–466. doi:10.1093/annonc/mdg102.
   PubMed Web of Science ®Google Scholar
• Ramos TC, Vinageras EN, Ferrer MC, Verdecia BG, Rupale IL, Perez LM, Marinello GG, Rodriguez RP, Davila AL. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther. 2006;5:145–149. doi:10.4161/cbt.5.2.2334.
   PubMed Web of Science ®Google Scholar
• Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, Gonzalez M, Wilkinson B, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother. 2009;32:92–99. doi:10.1097/CJI.0b013e31818fe167.
   PubMed Web of Science ®Google Scholar
• Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, Gonzalez G, Mazorra Z, Lage A, Crombet T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14:840–846. doi:10.1158/1078-0432.CCR-07-1050.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Neninger E, Garcia B, Popa X, Viada C, Luaces P, Gonzalez G, Lage A, Montero E, Crombet T. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines. 2011;9:7. doi:10.1186/1476-8518-9-7.
   PubMedGoogle Scholar
• Rodriguez PC, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22:3782–3790. doi:10.1158/1078-0432.CCR-15-0855.
   PubMed Web of Science ®Google Scholar
• Santana H, Garcia G, Vega M, Beldarrain A, Paez R. Stability studies of a freeze-dried recombinant human epidermal growth factor formulation for wound healing. PDA J Pharm Sci Technol. 2015;69:399–416. doi:10.5731/pdajpst.2015.01052.
   PubMedGoogle Scholar
• Hahnefeld C, Drewianka S, Herberg FW. Determination of kinetic data using surface plasmon resonance biosensors. Methods Mol Med. 2004;94:299–320. doi:10.1385/1-59259-679-7:299.
   PubMedGoogle Scholar
• Pol E, Karlsson R, Roos H, Jansson A, Xu B, Larsson A, Jarhede T, Franklin G, Fuentes A, Persson S. Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. J Mol Recognit. 2007;20:22–31. doi:10.1002/jmr.804.
   PubMed Web of Science ®Google Scholar
• Klasse PJ. How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines. 2016;15:295–311. doi:10.1586/14760584.2016.1128831.
   PubMed Web of Science ®Google Scholar
• Poulsen TR, Jensen A, Haurum JS, Andersen PS. Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol. 2011;187:4229–4235. doi:10.4049/jimmunol.1000928.
   PubMed Web of Science ®Google Scholar
• Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014;11:41. doi:10.1186/1742-4690-11-41.
   PubMed Web of Science ®Google Scholar
• Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res. 2009;15:2397–2405. doi:10.1158/1078-0432.CCR-08-1627.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, et al. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol. 2014;9:205–214. doi:10.1007/s11523-013-0284-7.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, Lage A, Montero E. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine. 2008;26:4647–4654. doi:10.1016/j.vaccine.2008.07.003.
   PubMed Web of Science ®Google Scholar
• Saavedra D, Crombet T. CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol. 2017;8:269. doi:10.3389/fimmu.2017.00269.
   PubMed Web of Science ®Google Scholar
• Mould RC, AWK A, van Vloten JP, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW. Enhancing immune responses to cancer vaccines using multi-site injections. Sci Rep. 2017;7:8322. doi:10.1038/s41598-017-08665-9.
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol. 1996;19:176–183. doi:10.1097/00002371-199605000-00002.
   PubMed Web of Science ®Google Scholar
• Kim A, Sadegh-Nasseri S. Determinants of immunodominance for CD4 T cells. Curr Opin Immunol. 2015;34:9–15. doi:10.1016/j.coi.2014.12.005.
   PubMed Web of Science ®Google Scholar
• Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, et al. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett. 2016;12:4493–4504. doi:10.3892/ol.2016.5253.
   PubMed Web of Science ®Google Scholar
• Valenzuela NM, Schaub S. The biology of IgG subclasses and their clinical relevance to transplantation. Transplantation. 2018;102:S7–S13. doi:10.1097/TP.0000000000001816.
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193–216. doi:10.1146/annurev.bi.48.070179.001205.
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res. 2002;62:1364–1369.
   PubMed Web of Science ®Google Scholar
• Oji A, Noda T, Fujihara Y, Miyata H, Kim YJ, Muto M, Nozawa K, Matsumura T, Isotani A, Ikawa M. CRISPR/Cas9 mediated genome editing in ES cells and its application for chimeric analysis in mice. Sci Rep. 2016;6:31666. doi:10.1038/srep31666.
   PubMed Web of Science ®Google Scholar
• Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469–477. doi:10.1111/j.1365-2222.2009.03207.x.
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Tay F, Graf N, Sonderegger TJP, Kundig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–135. doi:10.1016/j.jaci.2011.08.036.
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res. 2001;21:167–171. doi:10.1089/107999001750133195.
   PubMed Web of Science ®Google Scholar
• Morera Y, Sanchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernandez-Bernal F, Martin Y, Garabito A, Pinero J, Bermudez C, et al. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine. 2017;35:3582–3590. doi:10.1016/j.vaccine.2017.05.020.
   PubMed Web of Science ®Google Scholar
• Collins AM, Jackson KJ. A temporal model of human IgE and IgG antibody function. Front Immunol. 2013;4:235. doi:10.3389/fimmu.2013.00235.
   PubMed Web of Science ®Google Scholar
• Esparis-Ogando A, Montero JC, Arribas J, Ocana A, Pandiella A. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. 2016;22:5887–5898. doi:10.2174/1381612822666160715132233.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Sci. 2017;108:53–60. doi:10.1111/cas.13111.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer. 2013;13:49. doi:10.1186/1471-2407-13-49.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol. 2013;139:367–378. doi:10.1007/s00432-012-1340-x.
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin. 2007;3:8–13. doi:10.4161/hv.3.1.3537.
   PubMed Web of Science ®Google Scholar
• Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, et al. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer. 2016;139:1391–1401. doi:10.1002/ijc.30182.
   PubMed Web of Science ®Google Scholar
• Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother. 2015;64:1609–1621. doi:10.1007/s00262-015-1766-5.
   PubMed Web of Science ®Google Scholar